Galmed Pharmaceuticals Ltd. (GLMD) Upgraded by Zacks Investment Research to Buy
Zacks Investment Research upgraded shares of Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) from a hold rating to a buy rating in a report published on Wednesday. They currently have $5.00 target price on the biopharmaceutical company’s stock.
According to Zacks, “Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company. It is focused on developing therapies for liver diseases and gallstones. Galmed Pharmaceuticals Ltd. is based in Tel Aviv, Israel. “
GLMD has been the topic of several other reports. FBR & Co set a $20.00 price target on shares of Galmed Pharmaceuticals and gave the stock a buy rating in a research note on Friday, August 5th. Roth Capital reaffirmed a buy rating and set a $6.00 price target on shares of Galmed Pharmaceuticals in a research note on Wednesday, July 6th. Maxim Group reaffirmed a buy rating and set a $9.00 price target (down from $24.00) on shares of Galmed Pharmaceuticals in a research note on Monday, August 1st. Finally, HC Wainwright reaffirmed a buy rating on shares of Galmed Pharmaceuticals in a research note on Thursday, June 30th. Five investment analysts have rated the stock with a buy rating, Galmed Pharmaceuticals presently has a consensus rating of Buy and a consensus target price of $12.40.
Galmed Pharmaceuticals (NASDAQ:GLMD) traded down 0.2186% during trading on Wednesday, reaching $4.6099. 2,013 shares of the company were exchanged. Galmed Pharmaceuticals has a 12 month low of $3.50 and a 12 month high of $10.20. The stock has a 50 day moving average price of $4.18 and a 200 day moving average price of $4.71. The firm’s market capitalization is $51.18 million.
Galmed Pharmaceuticals (NASDAQ:GLMD) last released its quarterly earnings results on Wednesday, August 3rd. The biopharmaceutical company reported ($0.39) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.35) by $0.04. On average, analysts expect that Galmed Pharmaceuticals will post ($1.51) EPS for the current fiscal year.
Galmed Pharmaceuticals Company Profile
Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company. The Company focuses on the development and commercialization of once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing its synthetic fatty-acid/bile-acid conjugate (FABAC), called aramchol.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Galmed Pharmaceuticals Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galmed Pharmaceuticals Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.